Acronym:
AR Operable GOJ
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
| Cancer Type | Stomach & Oesophageal | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II | Tumour Stream | Oesophageal Cancer |
| Age Range | 18 years and older | Cancer Stage | Clinical Trials - Cancer Stage |
| Sex | Both | Anticipated Start Date | |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Stomach & Oesophageal |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Oesophageal Cancer |
| Cancer Stage | Clinical Trials - Cancer Stage |
| Anticipated Start Date | |
| Anticipated End Date |
Trial Summary
AR is a single-arm, multi-centre, open-label, phase-II clinical trial with safety run in neo-adjuvant chemo-radiotherapy plus immunotherapy with avelumab (carboplatin paclitaxel-RT-Avelumab) in operable oesophageal/OG) adenocarcinoma
Lay Summary
Sponsor / Cooperative group
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Amitesh Roy | Not Yet Recruiting |